Isavuconazole Treatment of Cerebral and Pulmonary Aspergillosis in a Pediatric Patient With Acute Lymphoblastic Leukemia: Case Report and Review of Literature.
Antifungal Agents
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Aspergillus
/ drug effects
Child, Preschool
Female
Humans
Neuroaspergillosis
/ chemically induced
Nitriles
/ therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Prognosis
Pulmonary Aspergillosis
/ chemically induced
Pyridines
/ therapeutic use
Triazoles
/ therapeutic use
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
pubmed:
17
5
2019
medline:
1
1
2021
entrez:
17
5
2019
Statut:
ppublish
Résumé
Invasive aspergillosis in hematologic pediatric patients is an opportunistic infection that is difficult to treat, with a high mortality rate when localized in the central nervous system. We are describing a 3-year-old girl who was affected by acute lymphoblastic leukemia who developed cerebral and pulmonary aspergillosis during induction chemotherapy. The patient failed first-line voriconazole treatment because of being a CYP2C19 ultrarapid metabolizer and received effective isavuconazole therapy with no notable side effects.
Identifiants
pubmed: 31094909
doi: 10.1097/MPH.0000000000001508
pii: 00043426-202008000-00025
doi:
Substances chimiques
Antifungal Agents
0
Nitriles
0
Pyridines
0
Triazoles
0
isavuconazole
60UTO373KE
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e469-e471Références
SJ1 Lin, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–366.
De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821.
Caillot D, Latrabe V, Thiébaut A, et al. Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: a useful tool for diagnosis and assessment of outcome in clinical trials. Eur J Radiol. 2010;74:e172–e175.
Hicks JK, Crews KR, Flynn P, et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics. 2014;15:1065–1078.
Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(suppl 1):e1–e38.
Miyakis S, Van Hal SJ, Ray J, et al. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect. 2010;16:927–933.
Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–769.
Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433–444.
Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist. 2013;6:163–174.
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case control analysis. Lancet Infect Dis. 2016;16:828–837.
Desai A, Hope W, Neely C, et al. Identification of an isavuconazole dosing regimen for children aged 2-17 years. European Congress of Clinical Microbiology and Infectious Disease—Madrid, Spain. April 21–24, 2018. ePoster, Oral Pres. O0795.
Barg AA, Malkiel S, Bartuv M, et al. Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients. Pediatr Blood Cancer. 2018;65:e27281.
Marzolf G, Sabou M, Lannes B, et al. Magnetic resonance imaging of cerebral Aspergillosis: imaging and pathological correlations. PLoS One. 2016;11:e0152475.